2.82
price up icon2.55%   0.07
after-market After Hours: 2.84 0.02 +0.71%
loading
Esperion Therapeutics Inc stock is traded at $2.82, with a volume of 4.32M. It is up +2.55% in the last 24 hours and up +6.02% over the past month. Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.75
Open:
$2.78
24h Volume:
4.32M
Relative Volume:
0.63
Market Cap:
$568.58M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.3302
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+3.68%
1M Performance:
+6.02%
6M Performance:
+196.84%
1Y Performance:
+38.24%
1-Day Range:
Value
$2.71
$2.85
1-Week Range:
Value
$2.515
$2.85
52-Week Range:
Value
$0.6925
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Name
Esperion Therapeutics Inc
Name
Phone
734-887-3903
Name
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Employee
304
Name
Twitter
@esperioninc
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
ESPR's Discussions on Twitter

Compare ESPR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
2.82 636.96M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
145.06 63.85B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.08 44.34B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.41 42.21B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
19.42 22.15B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
432.69 19.60B 3.08B 1.24B 1.07B 25.61

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-18-24 Initiated Goldman Neutral
Dec-17-24 Initiated Cantor Fitzgerald Overweight
Jun-20-24 Downgrade BofA Securities Neutral → Underperform
Jan-03-24 Downgrade BofA Securities Buy → Neutral
Nov-20-23 Resumed JP Morgan Neutral
Aug-01-23 Upgrade Northland Capital Under Perform → Market Perform
Jun-15-23 Upgrade BofA Securities Underperform → Buy
Mar-16-23 Downgrade BofA Securities Neutral → Underperform
Mar-16-23 Downgrade Northland Capital Market Perform → Under Perform
Mar-07-23 Upgrade Credit Suisse Underperform → Neutral
Feb-27-23 Resumed BofA Securities Neutral
Feb-24-23 Upgrade Jefferies Hold → Buy
Feb-03-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Aug-03-22 Downgrade Credit Suisse Neutral → Underperform
May-05-22 Upgrade JP Morgan Underweight → Neutral
Mar-10-22 Initiated H.C. Wainwright Buy
Oct-19-21 Downgrade Credit Suisse Outperform → Neutral
Oct-14-21 Downgrade Morgan Stanley Equal-Weight → Underweight
May-05-21 Downgrade Stifel Buy → Hold
Apr-26-21 Resumed Credit Suisse Outperform
Mar-11-21 Initiated Morgan Stanley Equal-Weight
Feb-12-21 Downgrade Jefferies Buy → Hold
Feb-09-21 Downgrade Goldman Neutral → Sell
Jan-15-21 Downgrade BofA Securities Buy → Neutral
Nov-10-20 Upgrade Credit Suisse Neutral → Outperform
Sep-29-20 Resumed JP Morgan Underweight
Aug-11-20 Downgrade Credit Suisse Outperform → Neutral
Apr-01-20 Resumed BofA/Merrill Buy
Mar-17-20 Upgrade Citigroup Neutral → Buy
Feb-24-20 Downgrade Northland Capital Outperform → Market Perform
Feb-14-20 Downgrade Citigroup Buy → Neutral
Sep-16-19 Upgrade Goldman Sell → Neutral
May-29-19 Downgrade Goldman Neutral → Sell
May-06-19 Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19 Upgrade Goldman Sell → Neutral
Mar-13-19 Upgrade JP Morgan Underweight → Neutral
Jan-07-19 Reiterated Needham Strong Buy
Dec-13-18 Initiated Goldman Sell
Oct-29-18 Upgrade Northland Capital Market Perform → Outperform
Oct-16-18 Initiated BTIG Research Buy
Aug-17-18 Upgrade Citigroup Neutral → Buy
Jul-11-18 Downgrade Northland Capital Outperform → Market Perform
May-03-18 Downgrade JP Morgan Neutral → Underweight
May-02-18 Downgrade BofA/Merrill Buy → Underperform
View All

Esperion Therapeutics Inc Stock (ESPR) Latest News

pulisher
07:43 AM

Can Esperion Therapeutics Inc. stock reach $100 price targetSell Signal & Daily Volume Surge Trade Alerts - newser.com

07:43 AM
pulisher
06:17 AM

Will Esperion Therapeutics Inc. (0ET) stock benefit from mergersWeekly Risk Report & AI Forecast for Swing Trade Picks - newser.com

06:17 AM
pulisher
06:12 AM

Will earnings trigger a reversal in Esperion Therapeutics Inc.2025 Year in Review & Reliable Entry Point Trade Alerts - newser.com

06:12 AM
pulisher
02:32 AM

Why Esperion Therapeutics Inc. is moving todayMarket Risk Analysis & High Return Stock Watch Alerts - newser.com

02:32 AM
pulisher
08:33 AM

Applying Elliott Wave Theory to Esperion Therapeutics Inc.Rate Cut & Low Drawdown Momentum Trade Ideas - newser.com

08:33 AM
pulisher
08:06 AM

Can volume confirm reversal in Esperion Therapeutics Inc.2025 Market Overview & Safe Entry Point Identification - newser.com

08:06 AM
pulisher
05:19 AM

How high can Esperion Therapeutics Inc. stock goJuly 2025 Decliners & Advanced Technical Analysis Signals - newser.com

05:19 AM
pulisher
04:54 AM

Should you wait for a breakout in Esperion Therapeutics Inc.Market Trend Summary & Consistent Income Trade Ideas - newser.com

04:54 AM
pulisher
04:37 AM

How to use Fibonacci retracement on Esperion Therapeutics Inc.Market Weekly Review & Weekly Stock Performance Updates - newser.com

04:37 AM
pulisher
01:59 AM

Analyzing drawdowns of Esperion Therapeutics Inc. with statistical toolsProduct Launch & Real-Time Volume Analysis Alerts - newser.com

01:59 AM
pulisher
01:41 AM

Why Esperion Therapeutics Inc. stock is favored by top institutionsMarket Growth Review & Free Community Consensus Stock Picks - newser.com

01:41 AM
pulisher
Oct 19, 2025

Identifying reversal signals in Esperion Therapeutics Inc.Earnings Beat & Target Return Focused Picks - newser.com

Oct 19, 2025
pulisher
Oct 18, 2025

Update Recap: Why Esperion Therapeutics Inc. stock attracts high net worth investorsQuarterly Market Review & Consistent Income Trade Recommendations - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

Will Esperion Therapeutics Inc. stock sustain high P E ratiosPortfolio Risk Report & Daily Stock Momentum Reports - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Is Esperion Therapeutics Inc. stock cheap at current valuationMarket Trend Review & Short-Term Trading Opportunity Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - The Globe and Mail

Oct 17, 2025
pulisher
Oct 17, 2025

Esperion nominates ESP-2001 as preclinical candidate for PSC - BioWorld MedTech

Oct 17, 2025
pulisher
Oct 17, 2025

Breakouts Watch: How Esperion Therapeutics Inc. stock compares to growth peersJuly 2025 Trends & Smart Money Movement Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Cantor Fitzgerald maintains Overweight rating on Esperion stock at $9 price target - Investing.com

Oct 17, 2025
pulisher
Oct 17, 2025

How currency fluctuations impact Esperion Therapeutics Inc. stockBuy Signal & Fast Gain Swing Alerts - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade

Oct 17, 2025
pulisher
Oct 16, 2025

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis - GlobeNewswire

Oct 16, 2025
pulisher
Oct 16, 2025

IND filing goal 2026: Esperion nominates ESP-2001 as preclinical PSC candidate, $1B market - Stock Titan

Oct 16, 2025
pulisher
Oct 16, 2025

Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Support & Resistance & Real-Time Stock Movement Alerts - newser.com

Oct 16, 2025
pulisher
Oct 15, 2025

Published on: 2025-10-15 12:04:18 - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsJuly 2025 Trends & Real-Time Chart Breakout Alerts - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Esperion Therapeutics Inc. stock momentum explained2025 Geopolitical Influence & Low Risk High Reward Ideas - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

How to use a screener to detect Esperion Therapeutics Inc. breakoutsPortfolio Gains Report & Proven Capital Preservation Methods - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

What’s the recovery path for long term holders of Esperion Therapeutics Inc.Trend Reversal & Safe Investment Capital Preservation Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Will breakout in Esperion Therapeutics Inc. lead to full recovery2025 Performance Recap & Risk Managed Trade Strategies - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

5 Best Cheap Stocks Under $5 to Buy Right Now | Investing - Money US News.com

Oct 14, 2025
pulisher
Oct 14, 2025

Why analysts remain bullish on Esperion Therapeutics Inc. stockQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com

Oct 14, 2025

Esperion Therapeutics Inc Stock (ESPR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.72
price up icon 1.40%
$51.36
price up icon 3.17%
$10.31
price up icon 1.38%
drug_manufacturers_specialty_generic RDY
$14.75
price up icon 2.08%
$141.33
price up icon 0.89%
$432.69
price down icon 0.15%
Cap:     |  Volume (24h):